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with a gene dose-dependent increase of CSF total tau lev-
els (F 2, 626  = 7.0, p = 0.001) and the homozygous  CDC2 Ex6 
+ 7II genotype was signifi cantly more frequent among AD 
patients compared to controls (p = 0.006, OR = 1.57, 95% 
CI 1.13–2.17). Our results provide further evidence for an 
involvement of cdc2 in the pathogenesis of AD. 
 Copyright © 2005 S. Karger AG, Basel 
 Introduction 
 In 2000, three independent genetic studies reported a 
linkage of Alzheimer’s disease (AD) to two chromosome 
10 markers  [1–3] . We have recently reported that the cell 
division cycle  (CDC2) gene  [4] , located close to the mark-
er D10S1225 linked to AD  [1, 3] , may be responsible for 
the linkage signal detected on chromosome 10  [5] . We 
described a novel polymorphism in the  CDC2 gene, des-
ignated Ex6 + 7I/D, and found the homozygous variant 
 CDC2  Ex6 + 7II with a single base insert at position +7 
after exon 6 to be signifi cantly overrepresented in AD 
patients compared to controls  [5] .  
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 Abstract 
 We have recently reported that a polymorphism in the cell 
division cycle  (CDC2)  gene, designated Ex6 + 7I/D, is as-
sociated with Alzheimer’s disease (AD). The  CDC2 gene 
is located on chromosome 10q21.1 close to the marker 
D10S1225 linked to AD. Active cdc2 accumulates in neu-
rons containing neurofi brillary tangles (NFT), a process 
that can precede the formation of NFT. Therefore,  CDC2 
 is a promising candidate susceptibility gene for AD. We 
investigated the possible effects of the  CDC2 polymor-
phism on cerebrospinal fl uid (CSF) biomarkers in AD pa-
tients.  CDC2 genotypes were evaluated in relation to CSF 
protein levels of total tau, phospho-tau and   -amyloid (1–42)  
in AD patients and control individuals, and in relation to 
the amount of senile plaques and NFT in the frontal cortex 
and in the hippocampus in patients with autopsy-proven 
AD and controls. The  CDC2 Ex6 + 7I allele was associated 
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 Cdc2 (also designated cdk1 or p34 cdc2 ) is a cyclin-de-
pendent kinase involved in cell cycle regulation  [6] . To 
regulate cell cycle events, cdc2 must form a complex with 
its regulatory subunit cyclin B1  [7] and elevated expres-
sion of cyclin B has been found in the hippocampus in 
AD patients  [8] . The cdc2/cyclin B complex forces the 
cells to pass the G 1 /S checkpoint even in the absence of 
growth factors and DNA replication  [9] . This lack of 
DNA replication leads to arrest of the cell cycle in G 2 , 
through an inhibition of cyclin B  [9, 10] . Factors ex-
pressed in G 2  regulate hyperphosphorylation of tau and 
microtubule destabilization, which is responsible for seg-
regation of chromosomes during mitosis  [11] . Addition-
ally, cdc2 is known to be one of the kinases that phos-
phorylates the amyloid precursor protein (APP) at Thr668 
in the G 2 /M phase of the cell cycle  [12] , which may infl u-
ence amyloidogenic processing of APP in AD. 
 Hyperphosphorylated tau is the main component of 
neurofi brillary tangles (NFT) found in the AD brain  [13] . 
The main function of tau is to bind to and thereby stabi-
lize microtubule and the binding ability of tau is modu-
lated through phosphorylation  [14] . The active cdc2/cy-
clin B complex is localized in NFT-bearing neurons  [15] , 
and intraneuronal accumulation of active cdc2 can pre-
cede the deposition of paired helical fi lament tau, and can 
be present in the absence of   -amyloid (A  )  [16] . 
 The predominant late-onset form of AD (LOAD) is a 
genetically complex disorder probably involving a range 
of genetic factors combined with environmental infl u-
ences. In the vast majority of LOAD, there is no recogniz-
able pattern of classical Mendelian inheritance, although 
epidemiological, family and twin studies suggest a sig-
nifi cant proportion of LOAD being attributable to genet-
ic factors  [17] . The only established susceptibility gene is 
the apolipoprotein E gene  (APOE), which has been shown 
to modify both the risk and age at onset of LOAD  [18, 
19] . However, the   4 allele only accounts for a fraction of 
the estimated genetic component in sporadic AD patho-
genesis and hence, several susceptibility genes remain to 
be found. 
 To further investigate the relationship between the po-
tential susceptibility gene  CDC2 and AD, we analyzed 
988 individuals for the previously described  CDC2 Ex6 
+ 7I/D polymorphism  [5] . The individuals included in 
this study can be divided into a clinical and a neuropatho-
logical postmortem subgroup. To explore possible neuro-
biological effects of the  CDC2 polymorphism, we mea-
sured cerebrospinal fl uid (CSF) protein levels of total tau, 
phospho-tau and A   42  in the clinical subgroup. Autopsies 
from brain tissue were obtained from the neuropatho-
logical subgroup, and consequently the amount of senile 
plaques (SP) and NFT could be measured. The mean 
count of SP and NFT for each brain region could then be 
investigated in relation to the  CDC2 polymorphism. 
Since we wanted to have as high power as possible for 
each comparison, we performed an analysis including all 
individuals available for each trait. We chose to include 
all available AD patients and controls in our study since 
we had the opportunity to perform an association study 
on the  CDC2 gene in a much larger population compared 
with the one used in our previous paper  [5] . 
 Materials and Methods 
 Subjects 
 Included in the study were 788 patients with AD (306 men and 
482 women, mean age 75  8 7.8 years) and 200 controls (82 men 
and 118 women, mean age 73  8 9.1 years). They can be divided 
into a clinical (695 AD patients, 98 controls) and a neuropatho-
logical postmortem subgroup (93 AD patients, 102 controls). In the 
clinical subgroup, CSF samples were available for 560 (total tau), 
541 (phospho-tau) and 498 (A   42 ) AD patients and for 75 (total 
tau), 44 (phospho-tau) and 75 (A   42 ) control individuals. Neuro-
pathological examinations of brain tissue were available for the 
postmortem subgroup. 
 Clinically diagnosed patients underwent a thorough clinical in-
vestigation, which included a medical history, physical, neurologi-
cal and psychiatric examination, screening laboratory tests, ECG, 
X-ray of the chest, EEG, and computerized tomography of the 
brain. The diagnosis of probable AD was made according to the 
NINCDS-ADRDA criteria  [20] . None of the AD patients had a 
family history of dementia suggestive of autosomal dominant AD. 
Clinical controls were individuals without a history, symptoms or 
signs of psychiatric or neurological disease, malignant disease, or 
systemic disorders (e.g. rheumatoid arthritis, infectious disease). 
Individuals with Mini Mental State Examination (MMSE) scores 
 [21] below 28 were excluded as controls. The neuropathological AD 
patients fulfi lled the clinical NINCDS criteria for probable AD  [20] 
and met the neuropathological CERAD criteria for defi nitive AD 
 [22] . The postmortem examination revealed no infarcts or other 
changes that could account for the dementia. Two areas of the right 
hemisphere, the frontal lobe and the anterior part of the hippocam-
pal formation were fi xed in 10% buffered neutral formalin for 4–6 
weeks, and thereafter embedded in paraffi n blocks. Six-microme-
ter-thick sections were stained with Bielschowsky staining. The ab-
solute number of SP and NFT was counted in fi ve randomly se-
lected fi elds at a magnifi cation of  ! 125, and a mean count of SP 
and NFT was obtained for each brain region and rated on a four-
step scale (0 = no, 1 = mild, 2 = moderate, and 3 = severe)  [23] . All 
AD brains had a histopathological score above 5 (mean  8 SD 7.5 
 8 2.0). Neuropathological controls were individuals who had died 
from cardiac disease or malignant disease. Their medical records 
revealed no history of dementia, or psychiatric or neurological dis-
eases. The postmortem examination revealed no macroscopic in-
farcts, and all brains had a histopathological score  [23] of 4 or low-
er (mean  8 SD 1.3  8 1.4).  
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 Genetic Analysis  
 Genomic DNA was extracted from whole blood samples and 
brain tissue using the GenoPrep TM  DNA Blood kit and DNA 
MagAttract kit (Qiagen, Germany) together with the GenoM TM -48 
Robotic Workstation (GenoVision, Norway). Approximately 
10 mg of brain tissue or 100   l of whole blood was used for each 
extraction. The isolated genomic DNA was stored at –20  °  C until 
it was used for gene analysis. The primer sequences for the PCR 
amplifi cation of the  CDC2 gene were designed using the Lasergene 
4.0 software (DNAstar Inc., Madison, USA) according to the  CDC2 
genomic DNA sequence deposited in the NCBI database (accession 
No. 14739455 and D32223). PCR amplifi cation was performed 
with the forward primer 5  -GCACCATATTTGCTGAACTAG-3  
and the reverse primer 5  -GTCCTGTAAAGATTCCACTTC-3  
(Invitrogene, Life Technologies) in a fi nal volume of 50   l, contain-
ing approximately 20 ng of template DNA, 1.5 m M MgCl 2 , 200   M 
dNTPs, and 1.25 unit of Taq DNA polymerase in 1  ! PCR buffer 
and 0.4 pmol/  l of each primer with the following PCR program: 
95  °  C for 4 min, 35 cycles of 95  °  C for 1 min, 57  °  C for 45 s and 72  °  C 
for 1 min. A fi nal extension step of 72  °  C for 10 min completed the 
reaction. DNA sequencing was performed using cycle sequencing 
with fl uorescent dNTPs (ABI PRISM, Applied Biosystems, UK), 
separation by capillary electrophoresis and detection by laser-in-
duced fl uorescence in an ABI 3100 genetic analyzer (Perkin-Elmer, 
USA). The sequencing reactions were conducted in both the for-
ward and reverse directions using the primers previously de-
scribed. 
 CSF Collection 
 In both AD patients and controls, CSF samples were obtained 
by lumbar puncture in the L 3 /L 4  or L 4 /L 5  interspaces, under stan-
dardized conditions. A CSF volume of 12 ml was collected and 
gently mixed to avoid gradient effects followed by centrifugation 
to remove cell debris. All CSF samples were collected according to 
standard conditions and were then frozen and stored at –80  °  C 
pending biochemical analyses without being refrozen. Further de-
tails of CSF collection have been described earlier  [24] . 
 CSF Analysis 
 Levels of CSF total tau were determined using a sandwich 
 ELISA, a solid-phase enzyme immunoassay constructed to  measure 
both normal and hyperphosphorylated tau (Innotest TM  hTAU-Ag, 
Innogenetics, Ghent, Belgium)  [25] . The wells are coated with an 
antihuman tau monoclonal antibody, AT120. CSF samples are in-
cubated in these wells together with a pair of biotinylated tau-spe-
cifi c monoclonal antibodies, HT7 and BT2.  
 Quantifi cation of CSF phospho-tau was done using another 
sandwich ELISA (Innotest  phospho-tau 181P , Innogenetics), which 
specifi cally measures phospho-tau phosphorylated at Thr181  [26] . 
The detection limit for this ELISA for CSF samples is 20 pg/ml. To 
capture the protein, the monoclonal antibody HT7 was used. CSF 
samples and thereafter the biotinylated antibody AT270 were add-
ed, as described previously in detail  [26] .  
 CSF A   42  was determined using a sandwich ELISA (Innotest 
 A   1–42 , Innogenetics), specifi cally measuring the 42 amino acid 
fragment of A   42   [24, 27] . The monoclonal antibody 21F12, which 
is highly specifi c to the C-terminus of the A  peptide, was used as 
capturing antibody, and the biotinylated monoclonal antibody 
3D6, specifi c to the N-terminus, was used as detector. The sensitiv-
ity for the ELISA for CSF samples was 50 pg/ml.  
 All analyses were run on the same batch of antibodies and 
 ELISA plates. Day-to-day imprecision (coeffi cient of variation) for 
all biochemical analyses was less than 10%. 
 Statistics 
 Genotype and allele distributions for the  CDC2 Ex6 + 7I/D 
polymorphism were analyzed using the Pearson    2  test. Compari-
sons involving three or more groups were performed using analysis 
of variance (ANOVA) and since the CSF traits are slightly skewed, 
we also performed the nonparametric Kruskal-Wallis analysis of 
ranks. Odds ratios and 95% confi dence intervals were calculated 
according to Altman  [28] . Comparing observed and expected gen-
otype frequencies using a    2  test assessed deviations from the Har-
dy-Weinberg equilibrium. All analyses were performed using the 
SYSTAT program version 10.2 (SPSS Inc., Chicago, Ill., USA). 
 Ethics 
 All clinical evaluations were made without knowledge of the 
results from the genetic analyses. The local Ethics Committees ap-
proved the study. All patients and controls (or their closest rela-
tives) gave their informed consent to participate in the study, which 
was conducted in accordance with the provisions of the Helsinki 
Declaration. 
 Results 
 We studied the  CDC2 Ex6 + 7I/D gene variant in rela-
tion to quantitative measurements of total tau, phospho-
tau and A   42  proteins in CSF. All analyses were conduct-
ed in both AD patients and controls. We sought to sys-
tematically test for the potential impact of the  CDC2 Ex6 
+ 7I/D gene variant upon these AD-related quantitative 
traits, as well as MMSE scores, age at onset, and a neuro-
pathological index of plaque and tangle scores in autopsy-
confi rmed AD patients. Comparisons of these CSF traits 
between AD patients and controls have previously been 
performed demonstrating highly signifi cant differences, 
whereby higher total tau and phospho-tau levels and low-
er A   42  levels are evident in AD patients compared to 
controls  [29] , which was also true for the present sample 
( table 1 ). This represents the full extent of traits that are 
at present available for these subgroups. To model these 
effects, we tested each trait in turn using ANOVA to ex-
plore signifi cant differences in genotypic means. For CSF 
traits, this initial screen was performed in combined pa-
tients and controls. For MMSE and SP-NFT scores, this 
was only done in AD patients.  
 ANOVA omnibus tests were signifi cant for CSF lev-
els of total tau (F 2, 632  = 8.1; p = 0.0003), phospho-tau 
(F 2, 582  = 3.8; p = 0.023) and A   42  (F 2, 570  = 3.9; p = 0.021). 
There was no evidence of an effect upon MMSE scores, 
age at onset, or SP-NFT scores. Individuals homozygous 
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for the insertion allele had elevated total tau and phos-
pho-tau levels and reduced A   42  levels in CSF, consistent 
with what is expected from studies of average trait levels 
in patients and controls for a pathogenic allele ( fi g. 1 ). The 
potential pathogenic effect of this allele is also supported 
by fi ndings showing that it is elevated in AD patients 
compared to controls. Since the CSF traits are slightly 
skewed, we also considered it important to confi rm the 
signifi cance of effects with a nonparametric test. Signifi -
cances using the Kruskal-Wallis analysis of ranks were 
CSF protein AD Controls p values
Total tau 670.9813.9 (n = 560) 344.2819.4 (n = 75) <0.0001
Phospho-tau 83.781.5 (n = 541) 60.083.6 (n = 44) <0.0001
A42 478.486.5 (n = 498) 716.0823.1 (n = 75) <0.0001
Results are mean values 8 SEM. CSF protein levels between AD patients and controls 
have been compared using the Kruskal Wallis one-way ANOVA.
























































































































 Fig. 1. Circles represent individual values of protein levels of total tau, phospho-tau and A   42  in CSF.  a – c AD 
patients.  d–f Controls. Horizontal lines indicate the mean value in the respective group.  a Total tau mean values 
(in pg/ml  8 SEM) for II: 704.5  8 22.0; ID: 651.9  8 20.0; DD: 552.3  8 31.0.  b Phospho-tau levels for II: 87.2 
 8 2.5; ID: 81.7  8 2.2; DD: 76.7  8 3.9.  c A   42  levels for II: 461.0  8 8.4; ID: 495.5  8 11.4; DD: 481.5  8 19.9. 
 d Total tau  levels for II: 370.3  8 38.3; ID: 346.1  8 24.5; DD: 257.8  8 36.4.  e Phospho-tau levels for II: 61.0  8 
5.1; ID: 63.3  8 5.7; DD: 45.8  8 8.4.  f A   42  levels for II: 700.8  8 39.6; ID: 709.0  8 30.8; DD: 791.9  8 74.8. 
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p = 0.0002 for total tau, p = 0.065 for A   42  and p = 0.058 
for phospho-tau levels. 
 Given the potential for confounding that was intro-
duced by including both AD patients and controls in pre-
liminary analyses, we tested for a possible interaction us-
ing a second-order factorial ANOVA model, focusing on 
the total tau trait (on the basis of the weaker effects for 
A   42  and phospho-tau levels). This was also done to ex-
plore the potential interaction of age, gender, or  APOE 
genotype (specifi cally   4 carrier or noncarrier status). 
None of the interaction terms for any of these covariates 
was signifi cant. With special regard to the patients and 
controls, the same trends for  CDC2 Ex6 + 7I/D can be 
seen in both groups ( fi g. 1 ). A fi nal adjusted model, includ-
ing all of these covariates, was evaluated for the effect of 
the  CDC2 Ex6 + 7I/D marker on CSF total tau levels. 
This was highly signifi cant, but slightly attenuated in 
comparison to the unadjusted model (F 2, 626  = 7.0; p = 
0.001). We note that this fi nal p value survives formal 
Bonferroni correction for multiple testing given 6 omni-
bus tests for all quantitative traits, 3 nonparametric tests, 
4 interaction tests, and a fi nal adjusted test (p corrected  = 
0.014). 
 Genotype distributions for the  CDC2 Ex6 + 7I/D con-
formed to the Hardy Weinberg equilibrium in both AD 
patients and controls. Genotype and allele frequencies for 
the Ex6 + 7I/D marker are shown in  table 2 . The  CDC2 
 Ex6 + 7I/D genotype distribution differed signifi cantly be-
tween AD patients and controls (p = 0.017). Specifi cally, 
the homozygous  CDC2 Ex6 + 7II genotype (p = 0.006) and 
the  CDC2  Ex6 + 7I allele frequencies (p = 0.009) were 
signifi cantly increased in AD ( table 2 ). The odds ratio for 
having AD was 1.57 (95% CI 1.13–2.17) for the  CDC2 
 Ex6 + 7II genotype, and 1.35 (95% CI 1.07–1.7) for the 
 CDC2  Ex6 + 7I allele. The  APOE   4 genotype and allele 
frequencies were signifi cantly increased in AD (p  ! 0.0001; 
 table 2 ). Stratifi cation for age, gender, or  APOE   4 carrier 
status did not affect the results. There were no signifi cant 
differences in genotype or allele frequencies between the 
subgroups and the whole group. Additionally, there were 
no signifi cant differences in mean age and sex distribution 
between the clinical subgroup, used for comparisons be-
tween gene variants and biochemical parameters, and the 
whole group. We can therefore conclude that these sub-
groups are representative for the whole material in re-
sponse to these parameters. 
a Genotype frequencies
CDC2 II ID DD
AD (n = 788) 376 (47.7)** 336 (42.6)* 76 (9.6)
Controls (n = 200) 73 (36.5) 102 (51.0) 25 (12.5)
APOE No APOE 4 One APOE 4 Two APOE 4
AD (n = 787) 247 (31.4) 410 (52.1) 130 (16.5)***
Controls (n = 198) 136 (68.7) 56 (28.3) 6 (3.0)
b Allele frequencies
CDC2 I D
AD (n = 1,576) 1,088 (69.0)** 488 (31.0)
Controls (n = 400) 248 (62.0) 152 (38.0)
APOE APOE 4 negative APOE 4 positive
AD (n = 787) 247 (31.4) 540 (68.6)***
Controls (n = 198) 136 (68.7) 62 (31.3)
Figures in parentheses are percentages. * p < 0.05; ** p < 0.01; *** p < 0.0001. Geno-
type and allele frequencies have been compared using Pearson’s 2 test.
Table 2. CDC2 and APOE genotype and 
allele frequencies
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 Discussion 
 To explore possible effects of the  CDC2 Ex6 + 7I/D 
polymorphism on CSF biomarkers we examined AD pa-
tients in whom we measured CSF levels of total tau, phos-
pho-tau and A   42 . We found the  CDC2 polymorphism to 
be associated with elevated CSF total tau protein levels 
in AD patients. The  CDC2 I allele infl uenced CSF total 
tau protein levels in a dose-dependent manner, suggesting 
a biochemical effect and an involvement of cdc2 in the 
pathogenesis of AD. Interestingly, the same tendency 
could be seen in controls. This was, however, not signifi -
cant, probably due to less power since the sample size was 
smaller.  
 The results from the  CDC2  genotyping of the AD pa-
tients and controls were in line with our previous results 
 [5] where the homozygous  CDC2 Ex6 + II genotype was 
signifi cantly overrepresented in AD patients compared to 
controls. We note that  APOE   4, the strongest known ge-
netic risk factor for AD, was more frequent in AD pa-
tients compared to controls in our study group ( table 2 ). 
When we explored potential interactions of age, gender, 
or  APOE genotype, none of these covariates affected the 
results signifi cantly. This suggests that the relationship 
between the  CDC2 gene and AD is independent of  APOE 
  4 status. 
 Although mutations in the APP are causative for fa-
milial AD, the role of A  in sporadic AD is unclear. The 
amyloid cascade hypothesis suggests that deposition of 
A  into SP is the event causative for the formation of 
NFT and neurodegeneration  [30] . Tau pathology has 
been observed in the absence of SP in other neurodegen-
erative disorders, such as progressive supranuclear palsy, 
Pick’s disease and corticobasal degeneration. Alterna-
tively, cell cycle events may precede the formation of SP 
and NFT found in AD. The general assumption is that 
adult neurons in the brain are postmitotic and unable to 
re-enter mitosis and thereby lack the ability to divide; 
conversely, accumulating evidence shows that postmitot-
ic neurons in AD are able to re-enter the cell cycle. Spe-
cifi c cell cycle components have been found to be acti-
vated in the AD brain  [8, 15, 31] and altered regulation 
of cdks and cyclins point towards cell cycle activation in 
postmitotic neurons in AD  [31, 32] . The active cdc2/cy-
clin B complex is localized in NFT-bearing neurons  [15] , 
and this accumulation of active Cdc2 can occur before 
the formation of paired helical fi laments, and without in-
volvement of A   [16] . Cdc2 has been suggested to be one 
of the kinases involved in AD pathology since it is able 
to phosphorylate tau protein at sites known to be phos-
phorylated in AD  [16, 33, 34] . In the present study, we 
detected a nonsignifi cant trend towards increased phos-
pho-tau levels in patients with the  CDC2  II and ID geno-
types ( fi g. 1 b). In our ELISA method, we measured tau 
protein phosphorylated at residue 181, which is a rela-
tively isolated phosphorylation site in the proline-rich re-
gion  [25] and is preferentially phosphorylated by proline-
directed kinases  [35] . Even though it is evident that cdc2 
activity is increased in AD, it needs to be determined 
whether cdc2 alters tau phosphorylation in a direct or in-
direct manner.  
 Additionally, cell cycle events have been linked to neu-
ronal cell death  [36] . Several studies support the hypoth-
esis that cell cycle proteins are expressed in postmitotic 
neurons, thus force them to re-enter the cell cycle and by 
this means eventually cause neuronal death  [36] . Critical 
check points of the cell cycle regulate the destiny of the 
cell, towards further progression through the cell cycle, 
growth arrest or induction of an apoptotic pathway. In 
terminally differentiated cells, like neurons, an apoptotic 
response might prevent an improper activation of the cell 
cycle  [37] . Cdc2 activity is elevated in apoptotic cells and 
many of the sites on tau that are hyperphosphorylated 
during apoptosis are also found in the AD brain  [34, 38, 
39] . Cdc2 can induce phosphorylation of the Bcl-2 associ-
ated death agonist (Bad) at Ser128, which in turn results 
in activation of Bad-mediated apoptosis  [40, 41] , and 
 previous results have found elevated levels of Bad protein 
in the AD brains  [42] . Moreover, APP can be phosphory-
lated by cdc2, which results in altered A  production  [12] . 
In turn, A  can stimulate proliferating, drive cultured 
neurons into the cell cycle and thereby maintain the pro-
liferating signal  [43, 44] . 
 In summary, the present study further supports the 
involvement of cdc2 in AD and is in line with our previ-
ous study  [5] . The  CDC2 Ex6 + 7I allele infl uences CSF 
total tau protein levels in a dose-dependent manner where 
individuals with II and ID genotypes have elevated pro-
tein levels of CSF total tau compared to DD individuals. 
Biological studies of the cdc2 protein are needed to inves-
tigate how activity and expression are affected by the 
 CDC2 polymorphism.  
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